---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-100537"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:13:19.408382+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem partner reports 41% ORR for VS-7375 in heavily pre-treated KRAS G12D PDAC at ESMO 2025

## Summary
- ORR of 41% (24/59) in heavily pre-treated advanced KRAS G12D PDAC at 600 mg daily; DCR 96.7%.
- Month-four OS rate 92.2%, median OS not reached; median PFS 5.52 months, 4-month PFS rate 78.2%.
- 91.5% of patients had tumor reduction; 47% still on treatment; longest treatment >1 year.
- Safety: 30.3% Grade 3 TRAEs, 3% discontinuation due to TRAEs, no TRAE-related deaths; mean dose intensity 93%.

## SEC filing metadata
- accession: 0001104659-25-100537
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/0001104659-25-100537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/tm2529024d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-100537
- JSON: https://secwatch.observer/filing/0001104659-25-100537.json
- Plain text: https://secwatch.observer/filing/0001104659-25-100537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.